This time last year DDW was reflecting upon the drug discovery and development sector’s push towards artificial intelligence (AI), in particular generative AI and how it could inform research. Within that article included the news of BenevolentAI’s disappointing results of its Phase II clinical trial of… Read More
BenevolentAI has unveiled a major strategic overhaul, which it says will return the company to its founding TechBio mission. The company has initiated significant organisational and budgetary changes that extend into 2027 and is also exploring options to delist from Euronext Amsterdam. Kenneth Mulvany, Executive… Read More
AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI. This novel target for heart failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca. This is the first target to be selected from the extended… Read More
BenevolentAI has announced it will be reducing headcount by around 30% and closing its US office as part of a change of focus in its business priorities. The company says it will focus on its AI-driven drug discovery collaboration and proprietary pipeline, believing these will bring… Read More
BenevolentAI has dosed the first patients in Phase I first-in-human studies of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744, intended for the treatment of ulcerative colitis (UC). The topline data readout from this study is expected in the first quarter of 2024. UC is a chronic disease… Read More
BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS). BEN-34712 is an oral, potent and selective brain penetrant RARɑ𝛃 (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug… Read More
